Long Term Documentation of the Safety and Efficacy as Well as the Effects on Quality of Life and Work Productivity in Patients With Rheumatoid Arthritis Under HUMIRA® (Adalimumab) in Routine Clinical Practice (AGIL)
Phase of Trial: Phase IV
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms AGIL
- Sponsors AbbVie
- 10 Oct 2017 Status changed from recruiting to completed.
- 31 Aug 2017 Planned End Date changed from 1 Aug 2017 to 15 Sep 2017.
- 31 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 15 Sep 2017.